GLP-1 plus GHRH peptides for body composition: What the science says

What did @harry_glp1 actually say?

The creator describes using tesamorelin, a growth hormone releasing hormone (GHRH) analog, stacked with ipamorelin, while also on a GLP-1 medication. He says tesamorelin "tells your body to release more growth hormone" rather than supplying it directly, notes it requires a fasted state for injection, and credits the combination with improved muscle fullness and reduced abdominal fat over several weeks. He also plugs a research chemical supplier called Ebolab's Research with a discount code.

He started at 1 mg, moved to 2 mg, and layered in ipamorelin more recently. His core claim: GLP-1 drove the weight loss, but tesamorelin is "refining it" by changing how his muscles look and reducing visceral-area fat. He also correctly identifies tesamorelin as FDA-approved, citing its use in HIV-associated lipodystrophy.

Does the science back this up?

On the mechanism, he's broadly correct. On the personal outcomes, there's no way to separate variables here, and the supplier he's using is a significant red flag that changes the entire risk calculus.

Tesamorelin (brand name Egrifta) is indeed an FDA-approved GHRH analog. It works by binding to pituitary GHRH receptors and stimulating endogenous growth hormone secretion. The rationale for preferring it over exogenous GH, that it preserves the body's own pulsatile feedback loop, is pharmacologically sound. Stanley et al. (2012, NEJM) confirmed tesamorelin significantly reduced visceral adipose tissue in HIV-positive patients with lipodystrophy. Falutz et al. (2010, AIDS) showed the effect was sustained at 52 weeks but reversed after discontinuation.

The ipamorelin stack has less robust human data. Ipamorelin is a ghrelin mimetic that stimulates GH release through a separate receptor pathway. The combination is theoretically synergistic, but most supporting evidence comes from animal models or small-scale studies in older adults, not healthy adults doing body recomposition.

What did they get wrong (or right)?

He got the mechanism mostly right. He got the supplier choice badly wrong, and the attribution of results is too confident given how many variables he's running simultaneously.

The correct parts: tesamorelin is FDA-approved, the pituitary-preservation argument is real, and the fasted-state injection requirement is accurate. GH secretion is blunted by elevated insulin, so injecting after eating does reduce efficacy. Møller et al. (1995, Journal of Clinical Endocrinology and Metabolism) documented how postprandial insulin suppresses GH pulse amplitude.

The problems: He says "pituitary gland's natural state" but mangles the word badly enough that viewers may not understand what he's describing. More importantly, he's sourcing from a "research chemical" company. Tesamorelin sourced outside a licensed pharmacy has no verified purity, sterility, or dosing accuracy. The FDA approved Egrifta for a specific indication; compounded or gray-market versions carry entirely different risk profiles. Finally, attributing body composition changes to tesamorelin specifically, while simultaneously using a GLP-1 agonist, changing his training, and adding ipamorelin, is not something anyone can do reliably. This is anecdote, not evidence.

What should you actually know?

Tesamorelin has real clinical backing, but the version most people are actually getting through TikTok pipelines is not the FDA-approved drug, and that distinction matters enormously.

If you're curious about tesamorelin, the relevant facts are these. The clinical evidence supports visceral fat reduction in a specific patient population. Off-label use in otherwise healthy adults seeking body recomposition has not been validated in large controlled trials. The fasted injection protocol is pharmacologically grounded. The ipamorelin stack is theoretically reasonable but understudied in this context. And sourcing peptides from research chemical companies, which are not licensed pharmacies and are not subject to compounding regulations, means you genuinely do not know what you're injecting. A licensed telehealth provider working with an accredited compounding pharmacy is a categorically different situation. Talk to a clinician before touching any of this.